4.75
price down icon3.85%   -0.19
after-market After Hours: 4.80 0.05 +1.05%
loading
Taysha Gene Therapies Inc stock is traded at $4.75, with a volume of 2.28M. It is down -3.85% in the last 24 hours and up +50.79% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.94
Open:
$5.05
24h Volume:
2.28M
Relative Volume:
0.39
Market Cap:
$1.30B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-13.30
EPS:
-0.3571
Net Cash Flow:
$-82.52M
1W Performance:
+0.64%
1M Performance:
+50.79%
6M Performance:
+160.99%
1Y Performance:
+141.12%
1-Day Range:
Value
$4.735
$5.10
1-Week Range:
Value
$4.51
$5.33
52-Week Range:
Value
$1.05
$5.5082

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Name
Taysha Gene Therapies Inc
Name
Phone
(214) 612-0000
Name
Address
3000 PEGASUS PARK DRIVE, DALLAS
Name
Employee
73
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
4.75 1.35B 8.10M -92.72M -82.52M -0.3571
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-11-25 Initiated BofA Securities Buy
Jun-27-24 Initiated BMO Capital Markets Outperform
Apr-09-24 Initiated Piper Sandler Overweight
Feb-01-23 Downgrade Jefferies Buy → Hold
Jan-27-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-22 Downgrade Goldman Buy → Neutral
Mar-09-22 Initiated Robert W. Baird Outperform
Mar-01-22 Initiated Wells Fargo Overweight
Feb-18-22 Initiated SMBC Nikko Outperform
Dec-16-21 Initiated Guggenheim Buy
Jul-16-21 Initiated Needham Buy
Jun-24-21 Initiated Truist Buy
Jun-15-21 Initiated BTIG Research Buy
Jun-09-21 Initiated Wedbush Outperform
Jun-08-21 Initiated JMP Securities Mkt Outperform
May-19-21 Initiated Cantor Fitzgerald Overweight
May-11-21 Resumed Jefferies Buy
Feb-24-21 Initiated William Blair Outperform
Jan-05-21 Initiated Oppenheimer Outperform
Oct-19-20 Initiated Chardan Capital Markets Buy
Oct-19-20 Initiated Goldman Buy
Oct-19-20 Initiated Jefferies Buy
Oct-19-20 Initiated Morgan Stanley Overweight
View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

pulisher
12:57 PM

Can Taysha Gene Therapies Inc. stock sustain institutional interestGap Up & Free Reliable Trade Execution Plans - newser.com

12:57 PM
pulisher
04:40 AM

Why Taysha Gene Therapies Inc. stock is rated strong buyJuly 2025 Retail & Weekly Momentum Picks - newser.com

04:40 AM
pulisher
04:19 AM

How institutional ownership impacts Taysha Gene Therapies Inc. stockJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - newser.com

04:19 AM
pulisher
01:44 AM

Candlestick signals on Taysha Gene Therapies Inc. stock todayJuly 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com

01:44 AM
pulisher
Oct 23, 2025

Why Taysha Gene Therapies Inc. stock is favored by top institutionsPortfolio Growth Summary & Real-Time Sentiment Analysis - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Taysha regains full rights to TSHA-102 gene therapy for Rett - Rett Syndrome News

Oct 22, 2025
pulisher
Oct 21, 2025

Chart overlay techniques for tracking Taysha Gene Therapies Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Tick level data insight on Taysha Gene Therapies Inc. volatilityQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Raymond James Initiates Coverage on TSHA with Strong Buy Rating - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Taysha soars on FDA breakthrough therapy status for lead asset - MSN

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 00:17:01 - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Why Taysha Gene Therapies Inc. is moving todayPortfolio Risk Summary & Real-Time Market Sentiment Reports - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Taysha Gene Therapies Inc. stock continue dividend increasesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Oct 20, 2025
pulisher
Oct 20, 2025

Using R and stats models for Taysha Gene Therapies Inc. forecastingJuly 2025 Levels & Risk Managed Investment Signals - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

What analysts say about Taysha Gene Therapies Inc stockStock Correlation Metrics & Zero-Cost Stock Research by Professionals - earlytimes.in

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Eyes Volatility Amid Key Developments - StocksToTrade

Oct 19, 2025
pulisher
Oct 19, 2025

Taysha Gene Therapies Faces Challenging Market Following Recent Developments - timothysykes.com

Oct 19, 2025
pulisher
Oct 18, 2025

Retail Trends: Can Taysha Gene Therapies Inc. stock double in next 5 yearsJuly 2025 WrapUp & Weekly Stock Breakout Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Taysha Gene Therapies Inc. stock maintain growth story2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces Financial Pressure: Concerns Amid Heavy Losses​ - StocksToTrade

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Faces New Challenges Amid Market Volatility - timothysykes.com

Oct 18, 2025
pulisher
Oct 18, 2025

Aug Summary: Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Weekly Earnings: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Retail Activity & Low Drawdown Trading Strategies - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Can Taysha Gene Therapies Inc. stock hit record highs againStock Surge & Detailed Earnings Play Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Taysha Gene Therapies Inc Stock Analysis and ForecastInstitutional Holding Changes & Affordable Portfolio Growth - earlytimes.in

Oct 18, 2025
pulisher
Oct 17, 2025

How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies, Inc.Common Stock (Nasdaq:TSHA) Stock Quote | Oklahoma City NewsThe Oklahoman - FinancialContent

Oct 17, 2025
pulisher
Oct 17, 2025

Sell Signal: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com Australia

Oct 17, 2025
pulisher
Oct 17, 2025

Why Is Taysha Gene Therapies Stock Falling Friday? - Sahm

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

Earnings visualization tools for Taysha Gene Therapies Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Bring it back home: Taysha regains gene therapy as option expires - BioWorld MedTech

Oct 17, 2025
pulisher
Oct 17, 2025

I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - biopharmadive.com

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies regains full rights to TSHA-102 (TSHA:NASDAQ) - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies (TSHA) Rating and Price Target Reaffirmed by Chardan Capital | TSHA Stock News - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.

Oct 17, 2025
pulisher
Oct 17, 2025

Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock - Investing.com Canada

Oct 17, 2025
pulisher
Oct 17, 2025

Needham Reiterates Taysha Gene Therapies (TSHA) with "Buy" Ratin - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: 87% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews

Oct 17, 2025
pulisher
Oct 16, 2025

Taysha Gene Therapies price target raised to $9 from $8 at BofA - MSN

Oct 16, 2025

Taysha Gene Therapies Inc Stock (TSHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.26
price up icon 1.11%
$91.28
price up icon 2.21%
$29.89
price up icon 0.07%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Cap:     |  Volume (24h):